|
|
|
28.02.26 - 00:06
|
The Baldwin Group Announces Future Leadership Transition in its Underwriting, Capacity, and Technology Solutions Segment (Business Wire)
|
|
|
Amy Carlisle to be named CEO; Jim Roche to become Executive ChairmanTAMPA, Fla.--(BUSINESS WIRE)--The Baldwin Group (“Baldwin” or the “Company”) (NASDAQ: BWIN), a leading independent insurance brokerage and advisory firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced a long-planned leadership transition within its Underwriting, Capacity, & Technology Solutions (“UCTS”) operating group, effective January 1, 2027. Amy Carlisle will become Chief Executive Officer of UCTS, succeeding Jim Roche, who will assume the role of Executive Chairman, UCTS for a period of three years. The transition reflects a deliberate, multi-year succession plan designed to ensure continuity and support the long-term strength and performance of the UCTS business.
As CEO, UCTS, Ms. Carlisle will oversee the segment's MGA and wholesale businesses, capacity operations, and finance and accounting functions. She will report to Chief Executive Officer, Trevor Baldwi...
|
|
|
|
|
27.02.26 - 19:54
|
Trump lobt Novartis-Chef für Schaffung von Arbeitsplätzen in USA (Cash)
|
|
|
- US-Präsident Donald Trump lobt den Konzernchef von Novartis für dessen Reaktion auf die US-Zölle. «Die Zölle haben Novartis und dessen grossartiger CEO Vasant (Vas) Narasimhan, M.D., dazu bewegt, 7+ Produktions- und Forschungsanlagen zu errichten und so Tausende von Arbeitsplätzen zu schaffen», schrieb Trump am Freitagabend auf seiner Plattform Truth Social....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.02.26 - 12:30
|
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) (GlobeNewswire EN)
|
|
|
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for remibrutinib. The opinion supports its use as an oral treatment for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1‑antihistamine treatment.“The introduction of remibrutinib represents a major advancement, providing clinicians with an oral Bruton's tyrosine kinase inhibitor (BTKi) treatment, with improvements in symptoms observed as early as Week 1,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité Universitätsmedizin Berlin. “CSU continues to impose a substantial unmet medical need, as many patients struggle to achieve adequate disease control with currently available therapies.”The positive CHMP opinion is supported by results from the pivotal REMIX-1 and REMIX-2 Phase III trials. Remibrutinib ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
